Join Notable Labs at the 62nd ASH Annual Meeting – Dec 5-8, 2020

On December 3, 2020 Dr. Michael Spinner, from Stanford University, Department of Medicine, Division of Oncology, reported that it will present at the 2020 Virtual ASH (Free ASH Whitepaper) Annual Meeting an update to the recently published article in Blood Advances (Press release, Notable Labs, DEC 3, 2020, View Source [SID1234572228]). This study used Notable Labs’ fully automated ex vivo drug sensitivity screening platform to test living tumor biopsies from patients with MDS and related myeloid neoplasms, and to identify correlations between clinical and genomic features and ex vivo drug sensitivity. Titled Correlating Clinical and Genomic Features with Ex Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms, this follow-up analysis involved patients evaluated at Stanford MDS Center between 2016-2020 with a diagnosis of MDS, MDS/MPN, or secondary AML. Ex vivo drug sensitivity screening defined three distinct patient clusters with differential sensitivity to numerous drug classes. Specific mutations were associated with greater ex vivo sensitivity to specific drug classes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To hear more about this exciting study and more, visit the virtual poster hall on Monday, December 7th from 7:30 am-3:30 pm PST.

Our Notable team will be attending ASH (Free ASH Whitepaper) this year. Schedule a meeting with our team and learn more about Notable’s proprietary automated, high-throughput, high-content, ex-vivo functional screening platform using living tumor biopsies.

Biotech Boom Continues – Silverback Ups IPO Raise to $195 Million

On December 3, 2020 Silverback Therapeutics reported that it has upped the ante on their IPO not once but twice, from an initial $125 million raise, to $151.8 million, to now setting sights on a $195 million raise, a 56% increase (Press release, Silverback Therapeutics, DEC 3, 2020, View Source [SID1234572211]). The firm will offer 10 million shares at a range of $19 to $20 apiece.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Silverback’s technology, ImmunoTAC, distinguishes itself from the competition by developing therapies that act only at the sites of disease, sparing healthy tissues from unwanted side effects. The platform pairs payloads that modulate disease-modifying pathways with monoclonal antibodies directed at specific disease sites. Its new class of targeted immuno-oncology agents direct a myeloid cell activator, which can permeate even solid tumors that are resistant to T-cell targeted immunotherapies.

The biotech’s pipeline is made up of TLR8 agonist candidates, with the lead currently in Phase I clinical study as a monotherapy to activate human myeloid cells in HER2-expressing tumors. Preclinical data on SBT6050 showed potential to maximize anti-tumor immune responses, even in tumors lacking T-cells. An update of interim data is expected in the second half of 2021.

This year has already brought in a good chunk of change for Silverback. In March, their oversubscribed Series B raked in $78.5 million. Then September brought the biotech $85 million more in a Series C. With a successful IPO, the company will have raised $405 million since its 2016 launch.

With industry-veteran Laura Shawver at the helm, Silverback hopes to prove their merit in treating highly prevalent forms of cancer – breast, gastric, NSCLC, bladder, TNBC, head & neck and other solid tumors.

After their most recent Series C, Shawver said, "Our new investors understand our fundamental science, our goal to help cancer patients, and the value creation potential of our programs. It’s awesome to have new partners in our journey along with current investors!"

Even amidst a deadly pandemic, Silverback’s announcement brings the biotech IPO record-breaking total to around 65 biotechs according to a tracker on BioPharma Dive. And the year isn’t quite over yet. Compared to the 38 biotech IPOs in 2019 and 45 in 2018, 2020 has the Nasdaq’s head spinning.

The company will trade under the symbol SBTX with Goldman Sachs, SVB Leerink and Stifel as joint bookrunners on the deal.

How can the $23B market for PD-1 blockers grow? ‘Pan-adjuvant’ use is key: report

On December 3, 2020 Immuno-oncology drugs that block the checkpoint PD-1 have been one of the biggest success stories in the pharma industry, creating blockbusters like Bristol Myers Squibb’s Opdivo and Merck’s Keytruda (Press release, Bristol-Myers Squibb, DEC 3, 2020, View Source [SID1234572206]). The embrace of the drugs to treat many types of metastatic cancer has created a $23 billion market.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

But that market is slowing, raising a worrisome question on Wall Street: How can companies like BMS and Merck continue to fuel the growth of PD-1 inhibitors?

The answer is in "pan-adjuvant" settings, in which patients are given PD-1 blockers before and/or after surgery along with other treatments to boost their chances of beating their cancer, analysts at Bernstein said in a note to investors earlier this week. For Merck and BMS, pan-adjuvant approvals could add at least $12 billion to their annual haul from PD-1 drugs in the next eight years—with the lion’s share of that going to Keytruda, they predicted.

FREE WEBINAR
What could you do with real-time supply chain information at your fingertips?
Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!
SAVE YOUR SPOT – REGISTER NOW
RELATED: ESMO (Free ESMO Whitepaper): Merck’s Keytruda matches Opdivo on key survival metric for post-surgery melanoma

BMS and Merck have already benefited from regulatory approvals of their PD-1 blockers in the post-surgery melanoma market, which brings in $1.4 billion for the companies, split between the two, the Bernstein analysts said. But beyond melanoma, pan-adjuvant settings "are untapped territories," they wrote.

That’s about to change. Merck and BMS have pivotal trials underway in 14 pan-adjuvant indications apiece, the analysts figure.

By far the biggest of those opportunities for Merck is non-small cell lung cancer (NSCLC). Merck’s pivotal pan-adjuvant Keytruda trials in NSCLC are likely to read out next year, and, if the program is a success, it could add $2 billion to the drug’s sales, the analysts estimated.

BMS’ pan-adjuvant program, meanwhile, is narrower that Merck’s, with the biggest opportunity likely to come from the melanoma market, which could generate an additional $1.7 billion in sales. Bernstein analysts projected that pan-adjuvant use of Opdivo in NSCLC would bring in $530 million.

RELATED: Bristol Myers’ Opdivo clears signs of lung cancer in first-in-class pre-surgery win

The analysts calculated the likelihood of success for PD-1 blockers in pan-adjuvant settings based on numerous factors, including the typical rate of cancer recurrence after surgery and how effective Opdivo and Keytruda have been as single agents in metastatic cancer. They tagged PD-1 blockers as having a 75% chance of succeeding in pan-adjuvant clinical trials for NSCLC. The drugs were also given 75% odds of succeeding in bladder cancer, cutaneous squamous-cell carcinoma, esophageal cancer and triple-negative breast cancer.

Still, competition will be challenging for all the players in the pan-adjuvant market. There are ongoing trials in adjuvant kidney cancer, not just of Opdivo and Keytruda, but also of PD-1 blockers from AstraZeneca and Roche, Bernstein analysts said. And even though the analysts predict Merck will take 40% market share in NSCLC, Roche’s Tecentriq could pose a threat.

All in all, the analysts see Merck bringing in $7.2 billion in sales of Keytruda in pan-adjuvant settings by 2028, not just from kidney cancer and NSCLC but also from melanoma and other cancers. "However, the range is broad and revenue can end up being as high as $17B," they wrote, especially if Keytruda outperforms competitors like Tecentriq with its data readouts.

BMS, for its part, will record $4.8 billion in pan-adjuvant sales of Opdivo by 2028, the analysts predicted. Even though six of the company’s 14 trials in pan-adjuvant settings will read out by the end of next year, "this is a very competitive market and we don’t expect Opdivo to be the market leader," they said.

As for the overall pan-adjuvant market for PD-1 inhibitors, stay tuned, the analysts advised. "We already have some early pan-adjuvant data, but the next 12 months are the ‘make-or-break’ period for these indications," they said.

Discovery Life Sciences and Scientist.com Partner to Advance Liquid Biopsy Development and Immunotherapy Research

On December 3, 2020 Scientist.com, the healthcare industry’s leading marketplace for outsourced research, and Discovery Life Sciences (Discovery), a global leader in biospecimen solutions, genomic, cell and immunohistochemistry (IHC) services, reported that have partnered to offer researchers online access to Illumina’s TruSight Oncology 500 (TSO500) technology (Press release, Discovery Life Sciences, DEC 3, 2020, https://www.businesswire.com/news/home/20201203005686/en/Discovery-Life-Sciences-and-Scientist.com-Partner-to-Advance-Liquid-Biopsy-Development-and-Immunotherapy-Research [SID1234572166]). The TSO500 technology was recently added to HudsonAlpha Discovery, Discovery’s highly regarded sequencing and bioinformatics laboratory.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"HudsonAlpha Discovery’s TSO500 platform combined with Discovery Life Sciences’ comprehensive biospecimen solutions, which are also available through Scientist.com, will accelerate immuno-oncology and liquid biopsy biomarker studies through delivery of actionable NGS data across patient-matched tumor and plasma biospecimens," stated Kevin Lustig, PhD, CEO and founder of Scientist.com. "This cutting-edge technology is now available to all Scientist.com users under one pre-established legal agreement, accelerating preclinical research and enabling faster science."

Illumina’s TSO500 solid Tumor (FFPE) and ctDNA technology enables genomic characterization across a broad range of tumor types through the identification of somatic variants from DNA and RNA, including critical immuno-oncology SNV, InDel, CNV and fusion biomarkers, as well as microsatellite instability (MSI) and tumor mutational burden (TMB).

"Our services are optimized for efficiency to enable rapid delivery of the valuable NGS data that only TSO500 provides across matched FFPE and plasma samples at any scale," stated Dr. Shawn Levy, PhD, Chief Scientific Officer at Discovery Life Sciences. "By making these new services available on Scientist.com, we will advance biomarker programs and allow researchers to more quickly develop and validate new immunotherapeutics, liquid biopsy diagnostics and companion diagnostics."

To learn more about applications for TSO500 technology watch the recent webinar, High Sensitivity TSO500 Detection of Somatic Variants in Matched FFPE and Plasma: Implications for Liquid Biopsy Biomarker Evaluations, featuring Dr. Levy of Discovery Life Sciences.

Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line

On December 3, 2020 Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), reported results from the ATLANTIS Phase 3 multicenter, randomized, controlled study evaluating Zepzelca (lurbinectedin) in combination with doxorubicin versus physician’s choice of topotecan or cyclophosphamide/doxorubicin/vincristine (CAV) for adult patients with small cell lung cancer (SCLC) whose disease progressed following one prior platinum-containing line (Press release, Jazz Pharmaceuticals, DEC 3, 2020, View Source [SID1234572157]). Patients received lurbinectedin at 2.0mg/m2 in the combination arm, which is lower than the FDA approved dose of Zepzelca at 3.2mg/m2.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study did not meet the pre-specified criteria of significance for the primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population comparing lurbinectedin in combination with doxorubicin to the control arm, though there was no adverse effect on OS with the experimental arm. Based on the study design, no additional hypotheses were formally tested. Importantly, key secondary and subgroup analyses favored the lurbinectedin combination arm. Lurbinectedin monotherapy was not tested in ATLANTIS.

The safety data in this study was consistent with the known safety profile of lurbinectedin monotherapy with no new safety signals observed. The experimental arm showed favorable safety and tolerability with regard to Grade-3 or greater drug related adverse events (AEs), deaths due to AEs, hematologic toxicity, dose reductions and treatment discontinuations due to AEs, compared to the control arm.

"Bringing Zepzelca to the U.S. market earlier this year alongside our partner, PharmaMar, was an important advance for adults with metastatic SCLC, an aggressive disease with a historically poor prognosis," said Robert Iannone M.D., M.S.C.E., executive vice president, research and development of Jazz Pharmaceuticals. "While the combination of lurbinectedin and doxorubicin did not achieve the primary endpoint in this study, the overall results support the activity and tolerability of lurbinectedin in this line of therapy. We look forward to the further development of lurbinectedin in SCLC and other tumors, both as monotherapy and in combination."

"We remain committed to improving outcomes for patients with metastatic small cell lung cancer where there is a high unmet medical need; we continue to evaluate the safety and efficacy of lurbinectedin in SCLC and other tumors. The drug’s activity in this disease and setting has been reinforced in this trial," said Luis Mora, managing director, oncology business unit, PharmaMar. "We extend our gratitude to the patients, physicians and their staff as well as caregivers who participated in this clinical study."

"Historically, patients with relapsed SCLC often face difficult odds due to the aggressive nature of the disease and they have had very limited treatment options. As a physician treating patients with SCLC, I’m confident in lurbinectedin as an effective new option in this traditionally challenging therapeutic area," Alberto Chiappori, MD, senior member of oncology and medicine for the Department of Thoracic Oncology at the H. Lee Moffitt Cancer Center and Research Institute and ATLANTIS Phase 3 study investigator.

Results will be discussed with the appropriate regulatory authorities and will be presented at a future medical meeting.

The U.S. Food and Drug Administration (FDA) approved Zepzelca under accelerated approval in June 2020 for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy. The approval is based on ORR and duration of response demonstrated in an open-label, monotherapy clinical study. The companies will provide the ATLANTIS data to FDA and look forward to working with the agency to determine the confirmatory data that is needed for full approval.

ATLANTIS Phase 3 Study Design
The ATLANTIS Phase 3 study enrolled 613 patients at 154 sites primarily in the U.S., Canada, Latin America and Western Europe from September 2016 through July 2018. Patients enrolled were ≥18 years with histologically or cytologically confirmed diagnosis of limited or extensive stage SCLC, had failed one prior platinum-containing regimen, and had a chemotherapy-free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ≥ 30 days. Patient inclusion criteria included small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on metastatic lesion(s) are eligible, if Ki-67/MIB-1 is expressed in >50 percent of tumor cells.

In the trial, patients were randomized in a 1:1 ratio to receive lurbinectedin in combination with doxorubicin or physician’s choice of topotecan OR cyclophosphamide/doxor ubicin/vincristine (CAV). The primary endpoint was overall survival. The secondary endpoints were 1) the difference in OS for patients in the lurbinectedin/doxorubicin arm compared to patients treated with CAV; 2) OS and progression free survival (PFS) in patients with or without CNS involvement; 3) PFS by independent review committee (IRC); 4) antitumor activity defined by objective response rate (ORR) per IRC; and 5) duration of response per IRC.

The study sample was stratified by the following factors: CTFI (chemotherapy free interval); ECOG performance status (0 vs. 1-2); CNS involvement vs. no involvement; prior immunotherapy against either programmed cell death protein-1 (PD-1) or programmed death ligand-1 (PD-L1); and investigator preference of topotecan and CAV.

About Zepzelca (lurbinectedin)
Zepzelca is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of the cell cycle and eventual cell death.1

Zepzelca for injection 4 mg is a prescription medicine used to treat adults with a kind of lung cancer called small cell lung cancer that has spread to other parts of the body (metastatic) and who have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working. Zepzelca is approved based on response rate and how long the response lasted. Additional studies will further evaluate the benefit of Zepzelca for this use.

Important Safety Information

Before receiving ZEPZELCA, tell your healthcare provider about all of your medical conditions, including if you:

have liver or kidney problems.
are pregnant or plan to become pregnant. ZEPZELCA can harm your unborn baby.
Females who are able to become pregnant:
Your healthcare provider should do a pregnancy test before you start treatment with ZEPZELCA.
You should use effective birth control (contraception) during treatment with and for 6 months after your final dose of ZEPZELCA.
Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZEPZELCA.
Males with female partners who are able to become pregnant should use effective birth control during treatment with and for 4 months after your final dose of ZEPZELCA.

are breastfeeding or plan to breastfeed. It is not known if ZEPZELCA passes into your breastmilk. Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your final dose of ZEPZELCA. Talk to your healthcare provider about the best way to feed your baby during treatment with ZEPZELCA.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ZEPZELCA works.

What should I avoid while using ZEPZELCA?

Avoid eating or drinking grapefruit, or products that contain grapefruit juice during treatment with ZEPZELCA.

ZEPZELCA can cause serious side effects, including:

Low blood cell counts. Low blood counts including low neutrophil counts (neutropenia) and low platelet counts (thrombocytopenia) are common with ZEPZELCA, and can also be severe. Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death. Your healthcare provider should do blood tests before you receive each treatment with ZEPZELCA to check your blood cell counts.
Tell your healthcare provider right away if you develop:
fever or any other signs of infection
unusual bruising or bleeding
tiredness
pale colored skin
Liver problems. Increased liver function tests are common with ZEPZELCA, and can also be severe. Your healthcare provider should do blood tests to check your liver function before you start and during treatment with ZEPZELCA.
Tell your healthcare provider right away if you develop symptoms of liver problems including:
loss of appetite
nausea or vomiting
pain on the right side of your stomach area (abdomen)
Your healthcare provider may temporarily stop treatment, lower your dose, or permanently stop ZEPZELCA if you develop low blood cell counts or liver problems during treatment with ZEPZELCA.

The most common side effects of ZEPZELCA include:

tiredness
low white and red blood cell counts
increased kidney function blood test (creatinine)
increased liver function blood tests
increased blood sugar (glucose)
nausea
decreased appetite
muscle and joint (musculoskeletal) pain
low level of albumin in the blood
constipation
trouble breathing
low levels of sodium and magnesium in the blood
vomiting
cough
diarrhea
These are not all of the possible side effects of ZEPZELCA.

Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Jazz Pharmaceuticals at 1-800-520-5568.

More information about Zepzelca, including Full Prescribing Information and Patient Information, is available here.

ZEPZELCA is a trademark of PharmaMar, S.A. used by Jazz Pharmaceuticals under license.